Roivant Sciences Ltd. (NASDAQ:ROIV) COO Eric Venker Sells 434,478 Shares

Roivant Sciences Ltd. (NASDAQ:ROIV) COO Eric Venker sold 434,478 shares of the business’s stock in a transaction on Monday, March 24th. The shares were sold at an average price of $10.82, for a total value of $4,701,051.96. Following the completion of the sale, the chief operating officer now owns 1,127,290 shares of the company’s stock, valued at $12,197,277.80. This trade represents a 27.82 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Eric Venker also recently made the following trade(s):

• On Thursday, March 20th, Eric Venker sold 315,522 shares of Roivant Sciences stock. The stock was sold at an average price of $11.06, for a total value of $3,489,673.32.
• On Thursday, February 20th, Eric Venker sold 100,000 shares of Roivant Sciences stock. The shares were sold at an average price of $10.65, for a total transaction of $1,065,000.00.
• On Thursday, February 13th, Eric Venker sold 218,041 shares of Roivant Sciences stock. The stock was sold at an average price of $10.42, for a total transaction of $2,271,987.22.
• On Tuesday, January 21st, Eric Venker sold 100,000 shares of Roivant Sciences stock. The stock was sold at an average price of $11.28, for a total transaction of $1,128,000.00.
• On Monday, December 30th, Eric Venker sold 177,704 shares of Roivant Sciences stock. The shares were sold at an average price of $11.54, for a total value of $2,050,704.16.
• On Friday, December 27th, Eric Venker sold 176,900 shares of Roivant Sciences stock. The stock was sold at an average price of $11.82, for a total value of $2,090,958.00.

Roivant Sciences Price Performance

Shares of ROIV stock traded up $0.04 on Monday, hitting $10.83. 6,976,198 shares of the company’s stock were exchanged, compared to its average volume of 5,636,264. The company has a 50 day moving average of $10.78 and a 200 day moving average of $11.46. The stock has a market cap of $7.73 billion, a P/E ratio of -72.20 and a beta of 1.26. Roivant Sciences Ltd. has a 12 month low of $9.93 and a 12 month high of $13.06.

Roivant Sciences (NASDAQ:ROIV) last posted its earnings results on Monday, February 10th. The company reported ($0.20) EPS for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.04. Roivant Sciences had a negative net margin of 119.54% and a negative return on equity of 14.05%. Sell-side analysts predict that Roivant Sciences Ltd. will post -0.92 EPS for the current fiscal year.

Institutional Trading of Roivant Sciences

A number of hedge funds and other institutional investors have recently modified their holdings of ROIV. Natixis Advisors LLC grew its position in Roivant Sciences by 8.3% during the 3rd quarter. Natixis Advisors LLC now owns 153,717 shares of the company’s stock worth $1,774,000 after acquiring an additional 11,726 shares during the last quarter. Swiss National Bank grew its holdings in shares of Roivant Sciences by 1.0% during the third quarter. Swiss National Bank now owns 721,046 shares of the company’s stock worth $8,321,000 after purchasing an additional 6,900 shares during the last quarter. Charles Schwab Investment Management Inc. increased its stake in shares of Roivant Sciences by 30.5% in the third quarter. Charles Schwab Investment Management Inc. now owns 2,767,412 shares of the company’s stock valued at $31,936,000 after buying an additional 646,627 shares during the period. Loomis Sayles & Co. L P raised its holdings in Roivant Sciences by 13.3% in the 3rd quarter. Loomis Sayles & Co. L P now owns 3,912,205 shares of the company’s stock valued at $45,147,000 after buying an additional 458,601 shares during the last quarter. Finally, The Manufacturers Life Insurance Company boosted its position in Roivant Sciences by 10.8% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 356,600 shares of the company’s stock worth $4,115,000 after buying an additional 34,641 shares during the period. Institutional investors own 64.76% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on the company. HC Wainwright reissued a “buy” rating and set a $18.00 target price on shares of Roivant Sciences in a report on Tuesday, February 11th. Cantor Fitzgerald upgraded shares of Roivant Sciences to a “strong-buy” rating in a research note on Tuesday, March 4th. One analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Roivant Sciences presently has an average rating of “Buy” and a consensus target price of $18.08.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.